TOP TEN perturbations for 1008_f_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1008_f_at
Selected probe(set): 204211_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1008_f_at (204211_x_at) across 6622 perturbations tested by GENEVESTIGATOR:

dendritic cell study 7 (IL-4 mddc) / dendritic cell study 7 (IL-15 mddc)

Relative Expression (log2-ratio):-3.8534517
Number of Samples:3 / 3
Experimental dendritic cell study 7 (IL-4 mddc)
Mature IL-4 dendritic cells differentiated from CD14+ monocytes obtained from healthy donors. Monocytes were seeded in RPMI and supplemented with 2.5 % heat-inactivated human AB serum. Monocytes were cultured with 800 IU/mL granulocyte macrophage colony-stimulating factor and 20 ng/mL IL-4 in order to generate immature IL-4 DCs. Conventional maturation cocktail, comprising 10 ng/mL tumor necrosis factor-α, 10 ng/mL interleukin-1β, 15 ng/ml interleukin-6 and 1 µg/mL prostaglandin E2 was added for 48 hours. CD14+ monocytes were isolated from peripheral blood mononuclear cells (PBMC) by Ficoll density gradient centrifugation and purified by positive magnetic cell selection.
Control dendritic cell study 7 (IL-15 mddc)
Mature IL-15 dendritic cells differentiated from CD14+ monocytes obtained from healthy donors. Monocytes were seeded in RPMI and supplemented with 2.5 % heat-inactivated human AB serum. Differentiation was induced with 800 IU/mL granulocyte macrophage colony-stimulating factor and 200 ng/mL IL-15 to obtain immature IL-15 DCs. A TLR-activating maturation cocktail, comprising 3 µg/mL R848, 2.5 ng/mL tumor necrosis factor-α, 250 ng/mL interferon-γ and 1 µg/mL prostaglandin E2 was added after 24-48 hours of differentiation for 18-20 hours. CD14+ monocytes were isolated from peripheral blood mononuclear cells (PBMC) by Ficoll density gradient centrifugation and purified by positive magnetic cell selection.

dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):2.9408484
Number of Samples:4 / 8
Experimental dendritic cell study 6 (gardiquimod; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

IFN-a2b study 1 / untreated immature dendritic cell sample

Relative Expression (log2-ratio):2.799983
Number of Samples:3 / 3
Experimental IFN-a2b study 1
Immature dendritic cells (DCs) treated with 1000 U/ml of IFN-a2b.
Control untreated immature dendritic cell sample
Immature dendritic cells (DCs) without IFN alpha treatment.

HIVGFP(G); SIVVLP(G) study 1 / uninfected monocyte-derived dendritic cell sample

Relative Expression (log2-ratio):2.7430286
Number of Samples:2 / 2
Experimental HIVGFP(G); SIVVLP(G) study 1
Monocyte-derived dendritic cell samples (MDDC) from isolated and stimulated CD14+ monocytes (GM-CSF and IL-4 for dendritic cell differentiation) of adult peripheral blood. MDDC were infected with GFP-encoding HIV-1 pseudotyped with VSV-G [HIVGFP(G)] and VSV-G-pseudotyped SIVmac239 virus-like particles [SIVVLP(G)] for 48 hours.
Control uninfected monocyte-derived dendritic cell sample
Monocyte-derived dendritic cell samples (MDDC) from isolated and stimulated CD14+ monocytes (GM-CSF and IL-4 for dendritic cell differentiation) of adult peripheral blood. MDDC were treated with lipopolysaccharide (LPS) for 48 hours.

LPS study 4 (shRNA cycT1) / cycT1 depletion study 2 (shRNA)

Relative Expression (log2-ratio):2.6952906
Number of Samples:2 / 2
Experimental LPS study 4 (shRNA cycT1)
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control cycT1 depletion study 2 (shRNA)
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then mock treated.

dendritic cell study 6 (gardiquimod) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):2.6681337
Number of Samples:7 / 8
Experimental dendritic cell study 6 (gardiquimod)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample

Relative Expression (log2-ratio):2.6583004
Number of Samples:2 / 2
Experimental LPS study 4 (shRNA contr.)
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control mock treated / transduced MONO-MAC-6 cell sample
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated.

HIVGFP(G); SIVVLP(G) study 1 / HIVGFP(G) study 1

Relative Expression (log2-ratio):2.6067047
Number of Samples:2 / 2
Experimental HIVGFP(G); SIVVLP(G) study 1
Monocyte-derived dendritic cell samples (MDDC) from isolated and stimulated CD14+ monocytes (GM-CSF and IL-4 for dendritic cell differentiation) of adult peripheral blood. MDDC were infected with GFP-encoding HIV-1 pseudotyped with VSV-G [HIVGFP(G)] and VSV-G-pseudotyped SIVmac239 virus-like particles [SIVVLP(G)] for 48 hours.
Control HIVGFP(G) study 1
Monocyte-derived dendritic cell samples (MDDC) from isolated and stimulated CD14+ monocytes (GM-CSF and IL-4 for dendritic cell differentiation) of adult peripheral blood. MDDC were infected with GFP-encoding HIV-1 pseudotyped with VSV-G [HIVGFP(G)] for 48 hours.

HIVGFP(G); SIVVLP(G) study 1 / SIVVLP(G) study 1

Relative Expression (log2-ratio):2.5682173
Number of Samples:2 / 2
Experimental HIVGFP(G); SIVVLP(G) study 1
Monocyte-derived dendritic cell samples (MDDC) from isolated and stimulated CD14+ monocytes (GM-CSF and IL-4 for dendritic cell differentiation) of adult peripheral blood. MDDC were infected with GFP-encoding HIV-1 pseudotyped with VSV-G [HIVGFP(G)] and VSV-G-pseudotyped SIVmac239 virus-like particles [SIVVLP(G)] for 48 hours.
Control SIVVLP(G) study 1
Monocyte-derived dendritic cell samples (MDDC) from isolated and stimulated CD14+ monocytes (GM-CSF and IL-4 for dendritic cell differentiation) of adult peripheral blood. MDDC were infected with VSV-G-pseudotyped SIVmac239 virus-like particles [SIVVLP(G)] for 48 hours.

IFNa-2a study 1 / normal monocyte sample

Relative Expression (log2-ratio):2.557518
Number of Samples:7 / 7
Experimental IFNa-2a study 1
Monocyte samples isolated from healthy donors and stimulated in vitro by 100 ng/ml IFNα2a in whole blood for 1.5 hour. Following stimulation, monocytes were depleted from granulocytes using CD15 MACS beads, and they were sorted from remaining peripheral blood leukocytes by CD14 labeling.
Control normal monocyte sample
Monocyte samples isolated from healthy subjects. Peripheral blood monocytes were isolated immediately after drawing blood by depletion from granulocytes using CD15 MACS beads, and afterwards they were sorted from remaining peripheral blood leukocyte by CD14 labeling.